Oramed Pharmaceuticals Inc. (ORMP)
ORMP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$4.17
-2.34% on the day
Market cap
$173.5M
Micro cap
Revenue · 2025
$2.0M
Prior year not contiguous
Net income · 2025
$75K
3.8% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ORMP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0001176309 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.0M |
| Net income | $75K |
| Operating income | -$15.1M |
| Net margin | 3.8% |
| Operating margin | -754.4% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $45.9M |
| Total assets | $230.9M |
| P/E (computed) | 2302.9× |
| P/S (computed) | 86.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2024-03-18 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-26 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-08-10 |
| Latest current report CURRENT REPORT | 8-K | 2026-09-17 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-08-03 |
Source: SEC EDGAR submissions feed, 941 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NGEN | NervGen Pharma Corp. | $1.63 | -5.78% | $173.5M |
| PEPG | PepGen Inc. | $2.50 | +0.40% | $173.1M |
| YARW | Yarrow Bioscience Inc. | $18.60 | -6.16% | $173.1M |
| WHWK | Whitehawk Therapeutics Inc. | $3.02 | -10.65% | $172.2M |
| VRXA | Veraxa Biotech AG | $1.20 | +5.26% | $169.7M |
| LYEL | Lyell Immunopharma Inc. | $7.51 | -9.19% | $184.0M |
| ADAG | Adagene Inc. | $2.46 | -10.22% | $162.5M |
| CNTN | Canton Strategic Holdings Inc. | $2.02 | -4.26% | $161.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier